6JULY - 2021TECH OUTLOOKEditorialStacey Smith Editor-in-Chiefeditor@pharmatechoutlook.comPublic healthcare forms a major component of modern governance. EU, specifically, in order to ramp up safety of medicines and reduce the risk of adverse drug reactions (ADRs) is taking pharmacovigilance and compliance to the next level through new legislations. And in the wake of the evolving EU regulations, it is becoming increasingly crucial for pharma organisations operating in this continent to be extremely meticulous in their pharmacovigilance processes.However, as pharmacovigilance is often a resource-intensive process, many organisations are currently transferring these compliance tasks to external vendors. While this route has its advantages, foresighted organisations will require to choose the more sustainable and cost-effective method of automating pharmacovigilance with advanced technologies. Specifically, the incorporation of AI, machine learning, and deep learning is expected to revolutionise the way pharma organisations view pharmacovigilance. By paving the way for complete automation of the repetitive, manual tasks and processes, these advanced technologies will streamline the more crucial operations like signal detection in drug safety, pharmacovigilance analytics, and benefit-risk assessment. Now, it is only a question of whether pharma organisations are ready to invest in the automation of pharmacovigilance. In this edition of Pharma Tech Outlook, we bring you the story of the top pharmacovigilance solution providers in Europe that deliver the best outcomes for their clients. This edition also offers a combination of thought leadership articles from subject matter experts and exclusive insights from CIOs and CXOs. We hope this edition will provide you with the right assistance in choosing the best pharmacovigilance solution provider according to your requirements.Let us know your thoughts!The New Era of Pharmacovigilance is AutomatedCopyright © 2021 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.JULY - 5 - 2021, Vol 07 - Issue 08 (ISSN 2644-2787) Published by ValleyMedia, Inc. To subscribe to Pharma Tech OutlookVisit www.pharmatechoutlook.com *Some of the Insights are based on the interviews with respective CIOs and CXOs to our editorial staffEditor-in-ChiefStacey SmithVisualizerChris LynnEditorial StaffAaron Pierce Ava GarciaJenna VegasCarolynn Walters Justin SmithPaul BarberSalesBrian Thomasbrian@pharmatechoutlook.comPhone: 510.556.2402sales@pharmatechoutlook.comeditor@pharmatechoutlook.commarketing@pharmatechoutlook.comEmail:Contact Us:Phone:510.556.2402, Fax:510-894-8405David ParkerTECH OUTLOOKTECH OUTLOOK
< Page 5 | Page 7 >